.2
WEBMD HEALTH CORP.
PRELIMINARY FINANCIAL INFORMATION
(in millions, except per share amounts)
(unaudited)
| Quarter Ended June 30, 2017 (Preliminary) |
||||
| Revenue |
$ | 176.0 | ||
|
|
|
|||
| Net income |
$ | 18.9 | ||
|
|
|
|||
| Interest, taxes, non-cash and other items (a) |
||||
| Interest income |
(1.9 | ) | ||
| Interest expense |
7.0 | |||
| Income tax provision |
11.9 | |||
| Depreciation and amortization |
7.6 | |||
| Non-cash stock-based compensation |
8.9 | |||
| Transaction expense |
2.1 | |||
| Other income |
(0.6 | ) | ||
|
|
|
|||
| Earnings before interest, taxes, non-cash and other items (“Adjusted EBITDA”) (b) |
$ | 53.9 | ||
|
|
|
|||
| Net income per common share: |
||||
| Basic |
$ | 0.51 | ||
|
|
|
|||
| Diluted |
$ | 0.43 | ||
|
|
|
|||
| Weighted-average shares outstanding used in computing income per common share: |
||||
| Basic |
37.1 | |||
|
|
|
|||
| Diluted |
54.4 | |||
|
|
|
|||
| (a) | Reconciliation of net income to Adjusted EBITDA. |
| (b) | See Annex A-Explanation of Non-GAAP Financial Measures. |
Additional information regarding preliminary results for the quarter ended June 30, 2017:
| • | Transaction expense represents professional fees incurred in connection with the |
process conducted by the Board of Directors to explore strategic alternatives
for the Company.
| • | Other income represents a gain on the sale of property. |